EP 1175246 A1 20020130 - UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
Title (en)
UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
Title (de)
STEIGERUNG DER TYPE III ENDOTHELIALZELL-STICKSTOFFOXID-SYNTHASE DURCH HMG-COA-REDUKTASE HEMMER
Title (fr)
REGULATION POSITIVE DE L'OXYDE NITRIQUE SYNTHASE DES CELLULES ENDOTHELIALES DE TYPE III PAR DES INHIBITEURS DE LA HMG-COA REDUCTASE
Publication
Application
Priority
- US 0007221 W 20000317
- US 27344599 A 19990319
Abstract (en)
[origin: WO0056403A1] A new use for HMG-CoA reductase inhibitors is provided. In the instant invention, HMG-CoA reductase inhibitors are found to upregulate endothelial cell Nitric Oxide Synthase activity through a mechanism other than preventing the formation of oxidative-LDL. As a result, HMG-CoA reductase inhibitors are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.
IPC 1-7
IPC 8 full level
A61K 31/00 (2006.01); A61K 31/198 (2006.01); A61K 31/365 (2006.01); A61K 31/366 (2006.01); A61K 31/505 (2006.01); A61K 31/519 (2006.01); A61K 31/7084 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 5/50 (2006.01); A61P 7/02 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 11/00 (2006.01); A61P 11/06 (2006.01); A61P 13/02 (2006.01); A61P 13/12 (2006.01); A61P 15/10 (2006.01); A61P 17/00 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); A61P 31/04 (2006.01); A61P 37/06 (2006.01); A61P 43/00 (2006.01); C12Q 1/02 (2006.01); C12Q 1/26 (2006.01)
CPC (source: EP)
A61K 31/00 (2013.01); A61K 31/365 (2013.01); A61K 31/366 (2013.01); A61K 31/505 (2013.01); A61K 31/70 (2013.01); A61K 31/7048 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2017.12); A61P 3/00 (2017.12); A61P 3/04 (2017.12); A61P 5/50 (2017.12); A61P 7/02 (2017.12); A61P 9/00 (2017.12); A61P 9/10 (2017.12); A61P 9/12 (2017.12); A61P 11/00 (2017.12); A61P 11/06 (2017.12); A61P 13/02 (2017.12); A61P 13/12 (2017.12); A61P 15/10 (2017.12); A61P 17/00 (2017.12); A61P 25/28 (2017.12); A61P 29/00 (2017.12); A61P 31/04 (2017.12); A61P 37/06 (2017.12); A61P 43/00 (2017.12)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0056403 A1 20000928; AU 3760300 A 20001009; CA 2368187 A1 20000928; EP 1175246 A1 20020130; EP 1175246 A4 20041215; JP 2003511347 A 20030325
DOCDB simple family (application)
US 0007221 W 20000317; AU 3760300 A 20000317; CA 2368187 A 20000317; EP 00916511 A 20000317; JP 2000606302 A 20000317